You are cordially invited to the Collaborative Innovation Forum 2023: Funding Disruptive Tech, hosted by the HKU Collaborative Innovation Center and Techno-Entrepreneurship Core.
Join us to discover the funding prospects in Hong Kong (ranging from HK$10 million to HK$100 million) and Mainland China (up to RMB10 million), along with invaluable expert insights to empower your research commercialisation journey!
Programme
| Date: | 1 November 2023 (Wed) |
| Time: |
9:15am - 1:30pm (registration starts at 9:00am) |
| Venue: | Tam Wing Fan Innovation Wing Two, G/F Run Run Shaw Building [Map] |
| Programme: |
Keynote: Bridging Research to Impact: BICI Funding Models and Case studies Dr. Xinjian Zhou, Co-President of Beijing Institute of Collaborative Innovation (BICI) and President of BICI USA, Director of BICI London |
|
Section 1: RAISe+: Driving Research Commercialisation (HK$10~100million grant) Mr. Pierre Wang, Assistant Director (Business Development), HKU Technology Transfer Office |
|
|
Section 2: Funding Opportunities for Disruptive Research (~RMB10million grant) Dr. Duoxiang Wang, President of Beijing Institute of Collaborative Innovation (BICI) |
|
|
Section 3: Panel Discussion: Meet the Scientist CEOs Facilitator: Mr. Paul Wang, Director, HKU Techno-Entrepreneurship Core Panellists: Dr. Junqi Wang, Founder and CEO, ChromX Health; Ms. Li Li, Investment Director, BASF Venture Capital; Professor Liu Pengtao, School of Biomedical Sciences, The University of Hong Kong; Dr. Xinjian Zhou, Co-President of Beijing Institute of Collaborative Innovation (BICI) |
|
| Note: Sections 2 and 3 will be conducted in Mandarin Chinese; a light lunch will be provided. |
Speakers
Dr. Duoxiang Wang
President of Beijing Institute of Collaborative Innovation (BICI), Ph.D. supervisor at the College of Engineering, Peking University, and Director of Jingjinji National Center of Technology Innovation and the Research Center for China's Industry-University-Research Integration and Innovation System.
Previously held positions as Chairman of Xiamen PKU Taipu Technology, Vice Dean of the College of Engineering at Peking University, and Vice President of Southern University of Science and Technology.
Dr. Xinjian Zhou
Co-President of Beijing Institute of Collaborative Innovation (BICI) and President of BICI USA, Director of BICI London.
Dr. Zhou received his B.S. and Ph.D. in Physics from Peking University and Cornell University, respectively. Before joining BICI, Dr. Zhou has worked in product development and system engineering as Senior/Staff Engineer at ASML, technology scouting and investment as Venture Manager at Technology-To-Business (TTB) center of Siemens, and technology transfer as BD director at Xerox Palo Alto Research Center (PARC).
Dr. Junqi Wang
Founder and CEO, ChromX Health
Dr. Wang is one of the global leaders in the field of micro gas chromatography technology. He participated in the founding and commercialization of Targeted Compound Monitoring, LLC and Kindwell Inc in US, and led the Kindwell Inc team to develop the company’s core technologies and products in the role of CTO. Incubated by BICI, ChromX Health is a high-tech company focused on developing revolutionary and innovative technologies to fully decode the metabolic molecular information in human breath. ChromX Health integrates Micro-Electro-Mechanical Systems (MEMS) and Artificial Intelligence (AI) in the analysis of biomarkers in breathomics for disease screening, diagnosis, and precision medicine.
Ms. Li Li
Investment Director, BASF Venture Capital
Ms. Li graduated from Fudan University majoring in Economics. Joining BASF Venture Capital in 2018, she is responsible for venture capital and invested company management in China. Her investment career began in the China M&A consulting department of PwC; she later joined Voith China andestablished China's M&A and corporate strategy department, focusing on researching opportunities inAsia's rail transit, energy, paper and other manufacturing industries; Ms. Li also served in the venturecapital department of Saudi Basic Industries Corporation and promoted the completion of the team’s first venture capital investment in China. BASF is an important foreign investment enterprise in China's chemical industry. It has invested more than 6 billion euros in Greater China to date (more than 9 billion euros jointly invested with partners).
Professor Liu Pengtao
School of Biomedical Sciences, The University of Hong Kong
Professor Liu is currently a professor at the School of Biomedical Sciences, The University of Hong Kong. He graduated from Henan Normal University with a Bachelor of Science (B.S.) in biology, and obtained his Master of Sciences from Chinese Academy of Sciences and Institute of Genetics. Pengtao Liu received a Ph.D. from Baylor College of Medicine (Houston, Texas, USA). Dr. Liu did his postdoc training at National Cancer Institute (Maryland, USA). Prior to joining The University of Hong Kong, Pengtao Liu was a Senior Group Leader and an affiliated faculty member at the Wellcome Trust-MRC Stem Cell Institute, University of Cambridge. Wellcome Trust, the EU and NIH funded researches in Liu lab.
About HKU Collaborative Innovation Center
The HKU Collaborative Innovation Center (HKUCIC) was jointly established by The University of Hong Kong (HKU) and Beijing Institute of Collaborative Innovation (BICI) in January 2023. Drawing on strengths from across different disciplines, HKUCIC serves as a hub to connect and engage HKU researchers in transferring university fundamental scientific and technological achievements into real productive forces.
About Techno-Entrepreneurship Core
Techno-Entrepreneurship Core (TEC) is the coordinating office to synergise and enhance HKU’s efforts in promoting innovation and entrepreneurship to build a vibrant ecosystem.